Melanotan I: selected references HeartPep literature library, reviewed 2026-11-20 https://heartpep.com/us/research/library/melanotan-i 1. Ugwu SO, Blanchard J, Dorr RT, et al. (1997). Skin pigmentation and pharmacokinetics of melanotan-I in humans Biopharmaceutics and Drug Disposition. DOI: https://doi.org/10.1002/(SICI)1099-081X(199704)18:3<259::AID-BDD20>3.0.CO;2-X PMID: 9113347 Source: https://pubmed.ncbi.nlm.nih.gov/9113347/ Verification: Abstract / bibliographic record. 2. Langendonk JG, Balwani M, Anderson KE, et al. (2015). Afamelanotide for Erythropoietic Protoporphyria New England Journal of Medicine. DOI: https://doi.org/10.1056/NEJMoa1411481 PMID: 26132941 Source: https://pubmed.ncbi.nlm.nih.gov/26132941/ Verification: Full text. 3. Dorr RT, Dvorakova K, Brooks C, et al. (2000). Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans Photochemistry and Photobiology. DOI: https://doi.org/10.1562/0031-8655(2000)072<0526:ieeati>2.0.co;2 PMID: 11045725 Source: https://pubmed.ncbi.nlm.nih.gov/11045725/ Verification: Abstract / bibliographic record. 4. Griffin LL et al. (2026). Acute impact of afamelanotide on UVR erythemal and melanogenic responses in healthy humans in vivo: an exploratory study Photochemical & Photobiological Sciences. DOI: https://doi.org/10.1007/s43630-026-00986-x PMID: 42678656 Source: https://link.springer.com/article/10.1007/s43630-026-00986-x Verification: Abstract / bibliographic record. 5. Seidl-Philipp M et al. (2026). Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients Journal der Deutschen Dermatologischen Gesellschaft. DOI: https://doi.org/10.1111/ddg.15996 PMID: 41793078 Source: https://onlinelibrary.wiley.com/doi/10.1111/ddg.15996 Verification: Abstract / bibliographic record. These are selected background references, not evidence that a HeartPep product or batch matches a studied preparation. Cite and assess the original papers.